Genetic variation in genes involved in hormones, inflammation and energetic factors and breast cancer risk in an admixed population

Carcinogenesis

Volumn 33, Issue 8, 2012, Pages 1512-1521

  Slattery, Martha L ^a   John, Esther M ^b,c   Torres Mejia, Gabriela ^d   Lundgreen, Abbie ^a   Herrick, Jennifer S ^a   Baumgartner, Kathy B ^e   Hines, Lisa M ^f   Stern, Mariana C ^g   Wolff, Roger K ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^c STANFORD CANCER INSTITUTE   (United States)

^d INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^e UNIVERSITY OF LOUISVILLE   (United States)

^f UNIVERSITY OF COLORADO   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE LKB1; PYRUVATE DEHYDROGENASE KINASE 2;

ADULT; AGED; AMERICAN INDIAN; ARTICLE; BREAST CANCER; CANCER RISK; CAUCASIAN; CONTROLLED STUDY; ENERGY TRANSFER; EUROPEAN AMERICAN; FEMALE; GENE FUNCTION; GENETIC VARIABILITY; HEALTH DISPARITY; HISPANIC; HOMEOSTASIS; HUMAN; IKAPPABKB GENE; INFLAMMATION; INSULIN METABOLISM; MAJOR CLINICAL STUDY; MTOR GENE; NFKAPPAB1 GENE; NFKAPPAB1A GENE; ONCOGENE; PDK2 GENE; POSTMENOPAUSE; PRIORITY JOURNAL; PRKAA1 GENE; PTEN GENE; RISK ASSESSMENT; RPS6KA2 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; STK11 GENE; TSC1 GENE;

ADULT; AGED; BREAST NEOPLASMS; ENERGY METABOLISM; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HORMONES; HUMANS; INFLAMMATION; MIDDLE AGED;

EID: 84865324708     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs163     Document Type: Article

References (53)

1. Slattery, M.L. et al. (2007) Body size, weight change, fat distribution and breast cancer risk in Hispanic and non-Hispanic white women. Breast Cancer Res. Treat., 102, 85-101.
2. Fejerman, L. et al. (2010) European ancestry is positively associated with breast cancer risk in Mexican women. Cancer Epidemiol. Biomarkers Prev., 19, 1074-1082.
3. Fejerman, L. et al. (2008) Genetic ancestry and risk of breast cancer among U.S. Latinas. Cancer Res., 68, 9723-9728.
4. Ziv, E. et al. (2006) Genetic ancestry and risk factors for breast cancer among Latinas in the San Francisco Bay Area. Cancer Epidemiol. Biomarkers Prev., 15, 1878-1885.
5. Slattery, M.L. et al. (2009) Convergence of hormones, inflammation, and energy-related factors: a novel pathway of cancer etiology. Cancer Prev. Res. (Phila)., 2, 922-930.
6. Carling, D. (2004) The AMP-activated protein kinase cascade-a unifying system for energy control. Trends Biochem. Sci., 29, 18-24.
7. Viollet, B. et al. (2003) Physiological role of AMP-activated protein kinase (AMPK): insights from knockout mouse models. Biochem. Soc. Trans., 31, 216-219.
8. Menon, S. et al. (2008) Common corruption of the mTOR signaling network in human tumors. Oncogene, 27 (suppl. 2), S43-S51.
9. Agarwal, A. et al. (2005) The AKT/I kappa B kinase pathway promotes angiogenic/metastatic gene expression in colorectal cancer by activating nuclear factor-kappa B and beta-catenin. Oncogene, 24, 1021-1031.
10. Woods, A. et al. (2003) LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr. Biol., 13, 2004-2008.
11. Hawley, S.A. et al. (2003) Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J. Biol., 2, 28.
12. Shaw, R.J. et al. (2004) The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl. Acad. Sci. U.S.A., 101, 3329-3335.
13. Lizcano, J.M. et al. (2004) LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J., 23, 833-843.
14. Carling, D. (2004) AMPK. Curr. Biol., 14, R220.
15. Pérez-Tenorio, G. et al. (2011) Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer. Breast Cancer Res. Treat., 128, 713-723.
16. Ng, T.L. et al. (2012) The AMPK stress response pathway mediates anoikis resistance through inhibition of mTOR and suppression of protein synthesis. Cell Death Differ., 19, 501-510.
17. Ahmed, M. et al. (2010) Osteopontin selectively regulates p70S6K/mTOR phosphorylation leading to NF-kappaB dependent AP-1-mediated ICAM-1 expression in breast cancer cells. Mol. Cancer, 9, 101.
18. Akcakanat, A. et al. (2008) Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases. Cancer, 112, 2352-2358.
19. Bartlett, J.M. (2010) Biomarkers and patient selection for PI3K/Akt/mTOR targeted therapies: current status and future directions. Clin. Breast Cancer, 10 (suppl. 3), S86-S95.
20. Baselga, J. (2011) Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist, 16 (Suppl 1), 12-19.
21. Bakarakos, P. et al. (2010) Immunohistochemical study of PTEN and phosphorylated mTOR proteins in familial and sporadic invasive breast carcinomas. Histopathology, 56, 876-882.
22. Beeram, M. et al. (2007) Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Ann. Oncol., 18, 1323-1328.
23. Buck, E. et al. (2006) Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol. Cancer Ther., 5, 2676-2684.
24. Campa, D. et al. (2011) Variation in genes coding for AMP-activated protein kinase (AMPK) and breast cancer risk in the European Prospective Investigation on Cancer (EPIC). Breast Cancer Res. Treat., 127, 761-767.
25. Dragowska, W.H. et al. (2007) Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin. Breast Cancer Res. Treat., 106, 319-331.
26. Janssen, E.A. et al. (2007) Comparing the prognostic value of PTEN and Akt expression with the Mitotic Activity Index in adjuvant chemotherapy-treated node-negative breast cancer patients aged <55 years. Cell. Oncol., 29, 25-35.
27. Lee, D.F. et al. (2007) IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell, 130, 440-455.
28. McAuliffe, P.F. et al. (2010) Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis. Clin. Breast Cancer, 10 (suppl. 3), S59-S65.
29. Mehta, M.S. et al. (2011) Polymorphic variants in TSC1 and TSC2 and their association with breast cancer phenotypes. Breast Cancer Res. Treat., 125, 861-868.
30. Edwards, S. et al. (1994) Objective system for interviewer performance evaluation for use in epidemiologic studies. Am. J. Epidemiol., 140, 1020-1028.
31. Liu, K. et al. (1994) A study of the reliability and comparative validity of the cardia dietary history. Ethn. Dis., 4, 15-27.
32. Slattery, M.L. et al. (1994) A computerized diet history questionnaire for epidemiologic studies. J. Am. Diet. Assoc., 94, 761-766.
33. DuBose, K.D. et al. (2007) Validation of a historical physical activity questionnaire in middle-aged women. J. Phys. Act. Health, 4, 343-355.
34. Angeles-Llerenas, A. et al. (2010) Moderate physical activity and breast cancer risk: the effect of menopausal status. Cancer Causes Control, 21, 577-586.
35. Sallis, J.F. et al. (1985) Physical activity assessment methodology in the Five-City Project. Am. J. Epidemiol., 121, 91-106.
36. Pereira, M.A. et al. (1997) A collection of Physical Activity Questionnaires for health-related research. Med. Sci. Sports Exerc., 29, S1-S205.
37. John, E.M. et al. (2003) Lifetime physical activity and breast cancer risk in a multiethnic population: the San Francisco Bay area breast cancer study. Cancer Epidemiol. Biomarkers Prev., 12, 1143-1152.
38. John, E.M. et al. (2005) Migration history, acculturation, and breast cancer risk in Hispanic women. Cancer Epidemiol. Biomarkers Prev., 14, 2905-2913.
39. John, E.M. et al. (2007) Sun exposure, vitamin D receptor gene polymorphisms, and breast cancer risk in a multiethnic population. Am. J. Epidemiol., 166, 1409-1419.
40. Falush, D. et al. (2003) Inference of population structure using multilocus genotype data: linked loci and correlated allele frequencies. Genetics, 164, 1567-1587.
41. Pritchard, J.K. et al. (2000) Inference of population structure using multilocus genotype data. Genetics, 155, 945-959.
42. Conneely, K.N. et al. (2007) So many correlated tests, so little time! Rapid adjustment of P values for multiple correlated tests. Am. J. Hum. Genet., 81, 1158-1168.
43. Holm, S. (1979) A simple sequentially rejective multiple test procedure. Scand J. Stat., 6, 65-70.
44. Galanter, J.M. et al. (2011) LACE concortium, development of a panel of ancestry informative markers for Latin Americans from genomewide data. In 12th International Congress of Human Genetics/61st Annual Meeting of the America Society of Human Genetics. Montreal, Canada.
45. Slattery, M.L. et al. (2007) IL6, aspirin, nonsteroidal anti-inflammatory drugs, and breast cancer risk in women living in the southwestern United States. Cancer Epidemiol. Biomarkers Prev., 16, 747-755.
46. Rollison, D.E. et al. (2010) Serum insulin-like growth factor (IGF)-1 and IGF binding protein-3 in relation to breast cancer among Hispanic and white, non-Hispanic women in the US Southwest. Breast Cancer Res. Treat., 121, 661-669.
47. Slattery, M.L. et al. (2007) Genetic variation in IGF1, IGFBP3, IRS1, IRS2 and risk of breast cancer in women living in Southwestern United States. Breast Cancer Res. Treat., 104, 197-209.
48. Murtaugh, M.A. et al. (2008) Diet patterns and breast cancer risk in Hispanic and non-Hispanic white women: the Four-Corners Breast Cancer Study. Am. J. Clin. Nutr., 87, 978-984.
49. Sánchez-Zamorano, L.M. et al. (2011) Healthy lifestyle on the risk of breast cancer. Cancer Epidemiol. Biomarkers Prev., 20, 912-922.
50. Haiman, C.A. et al. (2006) Common genetic variation at PTEN and risk of sporadic breast and prostate cancer. Cancer Epidemiol. Biomarkers Prev., 15, 1021-1025.
51. Stevens, K.N. et al.; GENICA Network; kConFab Investigators; Australian Ovarian Cancer Study Group. (2011) Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk. Br. J. Cancer, 105, 1934-1939.
52. Curran, J.E. et al. (2002) Polymorphic variants of NFKB1 and its inhibitory protein NFKBIA, and their involvement in sporadic breast cancer. Cancer Lett., 188, 103-107.
53. Sweeney, C. et al. (2007) Genetic admixture among Hispanics and candidate gene polymorphisms: potential for confounding in a breast cancer study? Cancer Epidemiol. Biomarkers Prev., 16, 142-150.